Titan Pharmaceuticals, Inc. (TTNP)

Titan Pharmaceuticals, Inc. (TTNP) — VMCI valuation read

TTNP prints VMCI 38/100 inside the Healthcare sector, where the median sits at 50. The 12-point below-median delta is the cleanest single-number summary of Titan Pharmaceuticals, Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On TTNP, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** TTNP trades at 18.0x earnings, 0% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -0.8x leaves covenant headroom; that is the risk line for Titan Pharmaceuticals, Inc. on the trailing financials.

TTNP rose 1.2% over the trailing 7 days, with a -6.3% read on a 30-day basis.